Axovant Sciences Ltd.
AXON
NGS
Sector: Healthcare
Industry: Biotechnology
115.97
USD
0.22
(0.19%)
Optionable: Yes Market Cap: 8,049 M 90-day average vol: 337,564
Previous close: 115.75 Open: 116.09 Bid: 116.74 Ask: 116.74
52 week range
82.49 209.00
Last updated: Tuesday 4th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Financials
AXON Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 115 M | 138 M | 165 M | 198 M | 268 M | 344 M | 420 M | 531 M | 681 M | 863 M |
| Cost of sales | 35 M | 43 M | 58 M | 64 M | 93 M | 128 M | 146 M | 207 M | 246 M | 295 M |
| Gross operating profit | 73 M | 90 M | 102 M | 129 M | 171 M | 207 M | 263 M | 313 M | 423 M | 550 M |
| Selling Gen & administrative expense | 38 M | 45 M | 54 M | 70 M | 108 M | 139 M | 151 M | 207 M | 301 M | 505 M |
| Research & development expense | 8 M | 10 M | 15 M | 24 M | 31 M | 55 M | 77 M | 101 M | 123 M | 194 M |
| Operating income | 20 M | 29 M | 33 M | 35 M | 32 M | 13 M | 25 M | -6 M | -14 M | -168 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 2 M | -1 M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income (EBT) | 23 M | 28 M | 32 M | 35 M | 31 M | 16 M | 28 M | 2 M | -6 M | -141 M |
| Income taxes | 8 M | 10 M | 12 M | 15 M | 14 M | 11 M | -1 M | 1 M | -5 M | -81 M |
| Net income from total operations | 15 M | 18 M | 20 M | 20 M | 17 M | 5 M | 29 M | 882000 | -2 M | -60 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 15 M | 18 M | 20 M | 20 M | 17 M | 5 M | 29 M | 882000 | -2 M | -60 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | 15 M | 18 M | 20 M | 20 M | 17 M | 5 M | 29 M | 882000 | -2 M | -60 M |
| Depreciation | 7 M | 5 M | 5 M | 5 M | 5 M | 9 M | 11 M | 11 M | 12 M | 19 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | 27 M | 35 M | 37 M | 39 M | 36 M | 21 M | 35 M | 5 M | -2 M | -149 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 0.27 | 0.35 | 0.38 | 0.37 | 0.33 | 0.1 | 0.52 | 0.01 | -0.03 | -0.91 |
| Diluted EPS total | 0.27 | 0.34 | 0.37 | 0.36 | 0.32 | 0.1 | 0.5 | 0.01 | -0.03 | -0.91 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today